ABBV 951 is filed in Japan to treat Parkinson's disease. AbbVie
AbbVie filed a new drug application (NDA) in Japan for its investigational advanced Parkinson’s disease treatment ABBV 951 (foslevodopa + foscarbidopa), which contains the prodrugs of levodopa and carbidopa. This is a continuous subcutaneous injectable agent developed by improving the molecular structure of levodopa and carbidopa.
Patients with advanced Parkinson’s disease undergo surgery to supplement dopamine through gastrostoma, Since the administration of ABBV 951 does not require surgery, AbbVie expects that this drug will reduce the burden on patients.
Related news and insights
The FDA has approved crizotinib (Xalkori) for the treatment of unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT) in adults and children over 1 year of age.
Bayer announced the FDA has approved a supplemental New Drug Application (sNDA) for the oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) with docetaxel for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Myovant Sciences and Pfizer Inc. announced that the FDA)has approved Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a one-pill, once-a-day therapy for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, with a treatment duration of up to 24 months.